Drug Coated Balloons as the New Standard of Care for Femoropopliteal In-Stent Restenosis: FAIR Assumption?
The femoropopliteal (FP) segment is increasingly treated via an endovascular-first approach for both lifestyle limiting claudication and critical limb ischemia. Nitinol stents have been shown to be superior to percutaneous transluminal angioplasty (PTA) and have become one of the primary modalities for the treatment of FP obstructive atherosclerotic disease due to improved structural integrity and conformability of newer devices1-3. Current nitinol stents have low rates of stent fracture and excellent clinical patency out to three years2,4. Despite these advances, FP in-stent restenosis (FP-ISR) remains an important clinical problem, occurring in up to 19-37% of cases following stenting of moderate length (up to 150mm) lesions and more frequently following treatment of longer lesions.1,2,5
- Received October 4, 2015.
- Accepted October 5, 2015.